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Abstract
With growing concerns over multidrug resistance microorganisms, particularly strains of bacteria and fungi, evolving to
become resistant to the antimicrobial agents used against them, the identification of new molecular targets becomes
paramount for novel treatment options. Recently, the use of new treatments containing multiple active ingredients has
been shown to increase the effectiveness of existing molecules for some infections, often with these added compounds
enabling the transport of a toxic molecule into the infecting species. Flavonoids are among the most abundant plant
secondary metabolites and have been shown to have natural abilities as microbial deterrents and anti-infection agents in
plants. Combining these ideas we first sought to investigate the potency of natural flavonoids in the presence of efflux
pump inhibitors to limit Escherichia coli growth. Then we used the natural flavonoid scaffold to synthesize non-natural
flavanone molecules and further evaluate their antimicrobial efficacy on Escherichia coli, Bacillus subtilis and the fungal
pathogens Cryptococcus neoformans and Aspergillus fumigatus. Of those screened, we identified the synthetic molecule 4-
chloro-flavanone as the most potent antimicrobial compound with a MIC value of 70 mg/mL in E. coli when combined with
the inhibitor Phe-Arg-ß-naphthylamide, and MICs of 30 mg/mL in S. cerevesiae and 30 mg/mL in C. neoformans when used
alone. Through this study we have demonstrated that combinatorial synthesis of non-natural flavonones can identify novel
antimicrobial agents with activity against bacteria and fungi but with minimal toxicity to human cells.
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Introduction
Bacterial pathogens often develop mechanisms of resistance to
different chemical compounds over time by adapting their
transporter systems to remove toxic compounds, such as drugs
and detergents, a mechanism identified over thirty years ago while
screening cancer drugs [1,2]. It has been established that efflux
pumps, particularly the resistance–nodulation–cell division (RND)
type CmeABC pump, have an important role in the antimicrobial
resistance of a number of pathogenic species [3,4]. Pathogenic
strains, of species such as Pseudomonas aeruginosa, Escherichia coli,
Staphylococcus aureus, and Salmonella enterica, that develop broad
substrate profiles become what is known as multidrug-resistant
(MDR) organisms and are a particular hazard to modern medical
practices. The latest antibacterial treatments are being developed
by screening collections of compounds against a panel of bacterial
pathogens in their MDR form and RND mutants to identify
improved or novel antibacterial activity [5].
Recent habits in the American diet has shown increased interest
in adopting healthy eating behaviors based on Asian and
Mediterranean diets in an effort to reduce their risk of heart
disease, diabetes, cancer and other lifestyle related disorders [6].
These same diets are often rich in plant polyphenols, such as
flavonoids and carotenoids, due to the increased consumption of
fruits and vegetables often involved in such diets. Flavonoids in
particular are known to have diverse pharmico-dynamic abilities,
which has drawn major attention to the molecules for both
personal health applications [7,8], and from pharmaceutical
companies keen on either their native nutraceutical properties
[9]. Increases to levels of polyphenolic substances have been
demonstrated in plants during fungal infection, suggesting that
these molecules may be part of the host-defense mechanism
[10,11].
Several recent reviews and studies have reported the antimi-
crobial efficacy of these molecules. Specifically, chalcones hybrids
have been shown to be potent against a range of organisms
including Staphylococcus aureus [12,13]. Numerous other studies
have identified antimicrobial activities of other flavonoid classes as
well [11,14,15,16,17,18,19]. Despite these efforts, flavonoids and
flavonoid-like molecules have failed to become treatment options
due to several factors including combinatorial-potency, molecule
toxicity and the fact that sufficiently large polyphenol libraries are
hampered by a low abundance in plant material or difficult
purification strategies. However, recent work has demonstrated
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pure quantities using recombinant production platforms
[20,21,22].
Since the antimicrobial effectiveness is thought to come from
flavonoids abilities to form complexes with both extracellular and
soluble proteins as well as bacterial membranes [23,24],
penetration into a cell and the maintenance of intracellular
concentrations in infecting species becomes a critical concern for
the development of flavonoids as the next generation of
antibacterial/fungal agents. In light of this we first aimed to
identify the natural potency of flavanones to limit E. coli growth in
the absence and presence of two RND efflux pump inhibitors.
Then, after creating a set of B-ring substituted, non-natural
flavanones with different functional groups, they were similarly
screened for their potency to stop or impede growth of not only E.
coli, but a range of organisms that included Bacillus subtilis,
Saccharomyces cerevisiae, and the fungal pathogens Cryptococcus
neoformans, Aspergillus fumigatus.
Materials and Methods
Chemical synthesis of non-natural flavanones
Benzaldehyde starting molecules were purchased from Sigma
Aldrich and Alfa Aesar. silica gel and sand were ordered from
Sigma Aldrich while the organic solvents were purchased from
EMD Biosciences. Chemical synthesis of synthetic flavanones has
been previously performed [25,26] and recently reviewed [27].
Briefly, the first steps include the production of a purified and
protected acetophenone from the 2,4,6-trihydroxy acetophenone
monohydrate. Following de-protection, acetophenone is com-
bined through a Claisen-Schmidt condensation with a slight
access of a benzaldehyde containing a substitution of interest to
be displayed in the B-ring. This results in the formation of the
pre-flavonoid intermediate chalcone, which is then purified and
de-protected overnight in HCl and methanol. A pH adjustment is
then used to carryout the ring closure to synthesize the final
flavanone molecule with the B-ring substitution. Solvent evapo-
ration is then used to obtain crystals of desired flavanone
molecule to be purified by flash chromatography. Verification of
flavonoids was done using HPLC having retention times between
12 and 17 minutes using a solvent system and C18 column
previously described [28]. The flavanone structure is shown in
Figure 1 with functional groups attached to the B-ring in either
the 4- (R1)o r3 -( R 2)p o s i t i o n .
Strains and culture media
Bacterial strains Eschericha coli BW25113 and Bacillus subtilis
JH642 and the yeast Saccharomyces cerevisiae INVSc1 were obtained
from laboratory stocks. Clinical isolates of Cryptococcus neoformans
H99 and Aspergillus fumigatus H237 were used from prior laboratory
isolations. HeLa cells were purchased from ATCC as a model
human cell line for toxicity testing.
Luria Broth (LB) from Sigma Aldrich was used for the growth of
E. coli strain while a homemade LB containing 10 g/L peptone,
10 g/L NaCL, and 5 g/L yeast extract (Difco) was used to culture
B. subtilis. YPD media (Difco) was used for cultures of S. cerevisiae.
Culturing of C. neoformans and A. fumigatus was done in a filter
sterilized synthetic dextrose (SD) media containing 0.57% yeast
base nutrients without amino acids (Difco) and 2% dextrose
(Fisher). Dulbeco’s Modified Eagle Medium (DMEM) media
containing 10% FBS and 1% glutamine was used for HeLa cell
cultures.
Potency assay and CFU assay
The cell densities of overnight cell cultures for bacterial or
fungal strains were first measured and then diluted to reach a
normalized optical density at 600 nm (OD600) of 0.1. For the
fungi C. neoformans and A. fumigatus, overnight cultures were
diluted in 96-well plates to 10
6 s p o r e sp e rm La sd e t e r m i n e db ya
hemocytometer. The flavanone molecule to be assayed was
dissolved in DMSO and then added to 96-well plates in
concentration ranging from 0.1 mM up to 2 mM. All flavonoid
stocks were 2 mM so serial dilutions (of 1:2) were used to create
the concentration series. The final DMSO concentration was
held constant at 5% for all testing. Dilute cell suspenstions in
growth media were then added to the wells with a final reaction
volume of 100 mL. Each flavonoid compound was also tested in
presence of two the efflux pump inhibitors Phe-Arg-ß-naphthy-
lamide (PABN) and 1-(1-Naphthylmethyl)-piperazine (NMP) with
concentrations of 25 mg/mL and 100 mg/mL respectively. All
assays were done in triplicate with DMSO controls. After assay
setup, the OD600 of each plate was measured using a BioTek
microplate reader and then incubated at 37uC for 24 hours
wrapped in paraffin to minimize evaporation with plates being
remeasured after incubation. Concentration at which no growth
was seen over the incubation period was deemed the Minimum
Inhibitory Concentration (MIC) for the compound under
investigation. To verify MIC values, dilutions were made to
obtain countable colonies from each well after being plated on
10% agar plates made from the respective growth medias.
Experimental controls without the flavonoid compound were
used throughout testing. The concentration for which the colony-
forming unit (CFU) count matched that of the control plates was
again deemed the MIC value.
Cytotoxicity assay
HeLa cell cultures were grown to confluence in supplemented
DMEM maintained at 37uC and in a humidified atmosphere
(90%) containing 5% CO2. Cell were washed once with
phosphate-buffered saline (PBS) then briefly incubated with
2 mL of cell dissociation buffer (Invitrogen) to detach adherent
cells. Cells were then seeded at 50,000 cells per mL in sterile 96-
well flouroscence plates for 24 hours with fresh media. After
incubation, 100 mL of the day-old media was replaced by 100 mL
of fresh media containing the modified flavanone at various
concentrations with the final DMSO concentration adjusted to
0.5% v/v in all conditions. Cell viability measurements were taken
after 3 hours and 24 hours of incubation at 37uC using the Cell
Titre-Blue Viability Assay kit from Promega as directed by the
manufacturer. All compounds were tested with 150 mg/mL in
triplicate with the appropriate DMSO only and cell free controls
used throughout.
Figure 1. Flavanone chemical structure. Non-natural flavanone
structures have functional groups attached to the B-ring in either the 4-
(R1)o r3 -( R 2) position.
doi:10.1371/journal.pone.0025681.g001
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Natural flavanones as bacteriostatic agents
To establish a base-line anti-microbial potency of flavanones in
general, we first tested the natural flavanones, namely naringenin,
pinocembrin and eriodictoyl, for their ability to limit the growth of
the gram-negative bacteria E. coli (Table 1). Overnight cultures of
E. coli in rich media failed to significant inhibit growth with natural
flavanones using the study’s maximum concentrations of 544 mg/
mL for naringenin, 512 mg/mL for pinocembrin and 576 ug/mL
for eriodictoyl. However, in the presence of the RND efflux pump
inhibitors NMP and PABN there was a significant reduction in the
growth ability of E. coli. To verify that the efflux pump inhibitors
were not acting as the growth inhibitory agents, MIC values for
NMP and PABN were similarly determined. With the MIC values
of 226 mg/mL for NMP and 52 mg/mL for PABN found for the
RND inhibitors alone, the respective concentrations (100 mg/mL
and 25 mg/mL) used in conjunction with the flavanones for
evaluating anti-microbal efficacy can be considered well within a
tolerable limit for E. coli growth. Similarly, the natural flavanones
were tested on the gram-positive bacteria B. subtilis both alone and
in the presence of NMP (Table 1). The inhibitor PABN was not
used against B. subtilis. While B. subtilis was found to be more
susceptible to the natural flavanones alone, they were more
effective at limiting growth in the presence of the RND efflux
pump inhibitor NMP.
Flavanone analog synthesis and antibacterial potency
In an effort to improve the bacterial toxicity of flavanones, a
small library of non-natural flavanones was created by chemical
synthesis, although large-scale synthesis can be accomplished
through microbial fermentations in a mutasynthses approach [20].
Synthesis of the non-natural flavanones was completed in four
reaction steps, which form protected chalcone intermediates and
then follow with de-protection and ring closure. The eight non-
natural flavanone analogs constructed include the substitutions 2-
flouro- (2F-), 3-hydroxy- (3OH-), 3-flouro- (3F-), 4-chloro- (4Cl-),
4-flouro- (4F-), 4-flouro-3-bromo- (4F-3B-), 4-flouro-3-chloro- (4F-
3Cl-) and 4-flouro-3-methoxy- (4F-3OM-). Combinations of 4Cl-
and 3F- as well as other substitutions failed to obtain the proper
flavanone after synthesis and purification and were not pursued
further. Final products verified by HPLC were tested for their
antimicrobial potency against a range of microorganisms.
The library was first screened against the bacterial species E. coli
and B. subtilis in 96-well plate growth assays and CFU counting
assays (Table 2). Similar to the natural flavanones, the non-natural
analogs alone failed to have any potent activity to limit growth of
E. coli. However in the presence of the RND inhibitor PABN, the
potency of the non-natural analogs was significantly increased by
up to 7-fold for 4-chloroflavanone. However, B. subtilis did show
significant sensitivity to the non-natural analogs both with and
without the efflux inhibitor NMP (Table 2). Importantly, the MIC
values for some compounds approach those of traditional
antibiotics such as kanamycin. All results were confirmed by both
triplicate cultures in 96-well plates and by CFU counting (data not
shown). It is important to note that 3OH-flavanone was found to
have a low aqueous solubility (approximately 2 mM), making the
potential production and use of this molecule challenging.
Antifungal efficacy non-natural flavanones
To further explore the potency of the flavanone analog library,
we tested the ability of these new molecules to inhibit the growth of
the non-pathogenic yeast S. cerevisiae and the pathogenic fungi C.
neoformans and A. fumigatus. Evaluating the growth inhibition of
each species was conducted in a similar manner to the bacterial
species but with incubations carried out at 30uC and incubation
times extended to account for slower doubling times of fungal
species. For C. neoformans and A. fumigatus, overnight cultures were
diluted in 96-well plates to 10
6 spores per mL. Furthermore, efflux
pump inhibitors were not used, as the RND systems are not
present in yeast and fungi. The natural flavanones failed to inhibit
growth in any of the species at concentrations used in the study
(data not shown), with one exception. Eriodictoyl was able to
completely inhibit growth of only S. cerevisiae with a MIC value of
Table 1. Natural flavanone MIC for bacteria.
E. coli B. subtilis
None NMP PABN None NMP
Naringenin .544 544 272 272 136
Eriodictoyl .576 .576 288 288 144
Pinocembrin .512 512 256 256 128
MIC values (ug/mL) are reported for natural flavanones against E. coli and B.
subtilis both without and with the efflux pump inhibitors NMP and PABN.
doi:10.1371/journal.pone.0025681.t001
Table 2. Non-natural flavanone MIC for bacteria.
E. coli B. subtilis
None NMP PABN None NMP
2F-FNN .548 .548 137 - -
3F-FNN .548 .548 137 137 137
3OH-FNN .546 .546 150 - -
4F-FNN .548 .548 137 55 27
4Cl-FNN .581 581 70 20 20
4F-3Cl-FNN .617 .617 .617 20 20
4F-3B-FNN .706 706 176 20 10
4F-3OM-FNN .608 304 250 304 80
MIC values (ug/mL) are reported for non-natural flavanones against E. coli and B.
subtilis both without and with the efflux pump inhibitors NMP and PABN.
doi:10.1371/journal.pone.0025681.t002
Table 3. Non-natural flavanone MIC for fungi and yeast.
C. neoformans A. fumigatus S. cerevisiae
Geneticin - - 36
Eriodictoyl - - 576
3F-FNN 55 274 55
3OH-FNN .540 .546 .546
4F-FNN 27 137 55
4Cl-FNN 30 145 30
4F-3Cl-FNN 31 617 .617
4F-3B-FNN 71 .706 35
4F-3OM-FNN 608 304 152
MIC values (ug/mL) are reported for non-natural flavanones against the yeast S.
cerevisiae and fungi C. neoformans and A. fumigatus.
doi:10.1371/journal.pone.0025681.t003
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known antifungal geneticin was identified at 36 mg/mL, which is
value slightly lower than the reported 100 mg/mL but may only be
due to a difference in strains used.
In contrast, MIC values were found for all of the non-natural
flavanones with some having significant antifungal capacity
(Table 3). Of the compounds tested, only the 3-hydroxyflavanone
failed to provide significant antifungal ability on any of the strains
tested. The yeast S. cerevisiae was found to be highly sensitive to 4-
chloroflavanone (30 mg/mL) and moderately sensitive to two
others (3-fluoro- and 4-fluoro-) with a MIC value of 55 mg/mL.
The most resistant of the three fungal species was A. fumigatus and
showed only limited growth inhibition with MIC values all greater
than 130 mg/mL. One the other hand, three of the four non-
natural flavanones tested demonstrated MIC values of approxi-
mately 30 mg/mL for the pathogenic C. neoformans. Figure 2 shows
serial dilution on agar growth plates of C. neoformans under different
exposure times to 4-chloroflavanone and indicates that the effect is
not inhibitory but fungacidal.
Effect of drugs on cell viability
One of the challenges of antifungal therapies is that the close
phylogenetic reslationship between fungi and mammals often
results in cross-kingdom toxicity. Novel antifungal agents thus
must ideally exhibit potent antifungal activity with minimal effect
on human cell viability. To address the question of cytotoxicity,
cell viability assays of the chemically synthesized drugs were
performed with the natural flavanone naringenin used as a
benchmark for cell toxicity. As a positive control, 5-fluorouracil
(5FU) was used and is widely applied chemotherapeutic agent in
gastrointestinal carcinoma [29]. Naringenin deemed to be
relatively non-toxic with cell viability at 81.6% after 24 hours
(Figure 3) using 150 mg/mL, however the 50% Lethal Dose (LD50)
value for 5-FU is 170 mg/mL at 24 hours. Importantly, while the
non-natural compounds were shown to be potent anti-microbial
agents, the cyotitoxicity was relatively low. The non-natural
analogs with fluorine substitutions were less toxic having cell
viabilities greater than 70% after 24 hours while those with
chlorine substitutions were relatively more cytotoxic.
Discussion
Antimicrobial resistance continues to evolve presenting serious
challenges to current medical practices to treat community-
acquired infections. Often the most talked about infections are
bacterial in nature from both gram-positive and gram-negative
species [30]. Hoever, fungal species also pose a serious burden on
our healthcare system. For example, Cryptococcus neoformans is a
major human fungal pathogen that particularly affects those with
compromised immune systems such as AIDS patients or organ
transplant recipients [31]. While only 7–15% of U.S. AIDS
patients develop cryptococcal infections, some areas of Africa, such
as Zimbabwe, have infection rates as high as 88% [32]. This
makes developing new antifungal agents a critical endeavor as
cryptococcal species are rapidly developing resistance to current
compounds.
Figure 2. Growth-inhibitory activity of 4-Cl-Flavanone (FNN)
against C. neoformans. Agar plate spotting in four 10-fold dilutions
after cell exposure to 4-chloroflavanone (4Cl-FNN) for 0, 15, 30 and
60 minutes at concentrations of 20, 25 or 30 mg/mL. DMSO was
included as a vehicle control.
doi:10.1371/journal.pone.0025681.g002
Figure 3. HeLa cell toxicity to non-natural flavanones. Relative
cell viability for HeLa cells after 3 hour and 24 hour incubations in the
presence of the natural flavanone naringenin and non-naturals 3-fluoro-
(3F-), 4-chloro- (4Cl-), 4-fluoro- (4F-), and 4-fluoro-3-chloro- (4Cl-3Cl-)
flavanones (FNN). 5-fluorouracil (5FU) was used as a positive control.
doi:10.1371/journal.pone.0025681.g003
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naturally occurring and chemically synthesized non-natural
analogs, to limit or stop the growth selected microorganisms
relevant to the medical community. Chemical modifications where
made to the B-ring of the flavanone, a position that has been
implicated in its biological activity [33,34]. Since halogens are not
common functional groups in nature, we looked to incorporate
these molecules into a variety of B-ring positions. While a small
variety of compounds was formed by chemical synthesis here,
these molecules have been routine synthesize from microbial
fermentations. Such a mutasynthesis route may be able to generate
a much more diverse library of compounds, with protein
engineering used to expand substrate specificity, and be able to
yield significantly larger quantities for broader spectrum testing.
The small collection of flavonoid derivatives tested in this study
was found to have up to a 15-fold decrease in MIC value against
bacteria when compared to natural flavanones and in the presence
of efflux pump inhibitors. The reduced MIC value for all
compounds in the presence of RND pump inhibitors illustrates
that these molecules are similarly transported across the cell
membrane as other antibacterial agents. Lower MIC values, as
high as a 10-fold reduction, were also seen for the non-natural
analogs against fungi. Furthermore, most of the compounds
displayed broad antimicrobial activity against all species tested
with one (4-chloroflavanone) showing significant antibacterial
activity against both bacteria and fungi. Finally, by verifying that
these non-natural flavanones displayed little to no toxicity to
mammalian cells, it shows a greater potential to used them as drug
candidates for further functional development and clinical testing.
In summary, this data suggest two opportunities for the
development of new antimicrobial therapeutics. First, combining
antibacterial compounds with efflux pump inhibitors is an efficient
way to increase the potency of the therapeutic agent. And
secondly, that introducing a variety of novel substitutions to
flavonoids, and other natural products in general, can create new
compounds that possess different discrete effects between fungi
and humans.
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